Home FDA labels ffd56eaf-0612-f8ad-e053-6394a90a8a25 FDA label ffd56eaf-0612-f8ad-e053-6394a90a8a25 openFDA label record# This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)
SPL set ID ad973b2a-e566-470e-9eca-950138b5c20b
SPL ID ffd56eaf-0612-f8ad-e053-6394a90a8a25
Version 3
Effective date 2023-07-06
Source export date 2026-11-13
Source partition 11
Source file https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
Source object key raw/openfda/drug-label/2026-11-13/0ccebc9befe0ec22afe916211b2687f6eef8ed163963720f103786a7f2d2e3ae/drug-label-0011-of-0014.json.zip
Source manifest SHA-256 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run 20261116T150851Z
Imported at 2026-11-16 17:35:24
Harmonized identifier links# Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
Harmonized identifiers page 1 of 1 · 2 matching rows.
Adverse reactions cross-check# openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions sections page 1 of 1 · 1 matching rows.
adverse reactions ADVERSE REACTIONS The frequency of adverse events reported in patients using nystatin topical powder is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS, General .)
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.